Login to get immediate access to this content.
LoginSpeaker: Séverine Guiu, France
Abstract discussed:
- 179O - Combination of olaparib, durvalumab, and fulvestrant in advanced ER-positive, HER2-negative breast cancer: Watch the presentation from ESMO Breast 2024 now
The speakers and studies featured in this video series were selected independently by ESMO.
Published July 2024